NCAM1 and neuroendocrine neoplasm: Additionally our findings show that CD56, CD117, and NSE, although relatively sensitive in neuroendocrine neoplasms at other sites, should not be used as markers of neuroendocrine differentiation in the breast as they have a very low specificity and are also expressed in a high frequency in normal breast tissue.